Come meet us

Presentation of the IVA337 phase IIb in NASH


Inventiva management team provided an overview of the ongoing development work with IVA337 in NASH during a Key Opinion Leader Breakfast hosted in New-York. The meeting featured a keynote presentation by Sven Francque, MD, (University of Antwerp), who provided an overview of the nonalcoholic steatohepatitis (NASH) market and discussed current and novel approaches to treatment.

A live webcast and subsequent replay of the event is available at

ACR annual meeting


ACR  annual meeting,  Washington DC,  11 -16 Nov  2016

Inventiva selected for an oral communication on IVA337 in lung fibrosis 

The abstract titled "Pan-PPAR Agonist IVA337 Is Effective in the Prevention of Experimental Lung Fibrosis and Related Pulmonary Hypertension" will be presented at the 2016 ACR/ARHP Annual Meeting, in Washington, DC, November 11-16.